-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
How a global registry could help solve Asia's diabetes crisis
Nov 14, 2016
Asia Pacific is in the midst of a diabetes epidemic that shows no signs of abating. Of the 415 million people worldwide with diabetes type I and II, more than half (232 million) live in Southeast Asia and the Western Pacific, according to 2015 data from the International Diabetes Federation. Among these countries, China has the largest diabetes epidemic, where 11.6 percent of Chinese adults have the disease. The social, economic and healthcare challenges related to this crisis in Asia already are enormous, and industry stakeholders are struggling to implement care strategies that meet the needs of this patient population.
In the lead up to World Diabetes Day on November 14, I wanted to share an exciting project I have been involved in that will help shed light on this widespread disease by providing physicians, researchers, payers and regulators with new insights into the way diabetic patients are diagnosed and treated in various Asian countries.
In November 2015, The American College of Cardiology (ACC) announced plans to join with the National Heart Centre Singapore (NHCS) and QuintilesIMS to create a global diabetes registry that will support diabetes and cardiometabolic research. Once it is fully launched, the Asian Diabetes Outcomes Registry (ADORE) will be a real-world, prospective, longitudinal, investigator-led registry that will collect comprehensive data for type 2 diabetes treatment patterns and outcomes throughout Asia by studying how patients are treated in everyday medical practice, and how they fare. The goal of this registry is to create a network of sites with thousands of patients in care settings throughout Asia — including, in China, South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Hong Kong, India, Vietnam and Sri Lanka — to fuel smarter research in this disease area.
Real-world data: no intervention required
Diabetes is not a one-size-fits-all disease. To begin to address the diabetes crisis in Asia Pacific, stakeholders first need to understand the unique attributes of these patients and their disease journey, and how they differ from diabetes patients in other regions. This would include gathering information about when and how they are diagnosed, what treatment paths they typically follow, who responds and who doesn’t, and whether the risk-benefit profiles for various treatments are the same among various Asian ethnicities. There are also likely to be substantial differences between Asian countries in the registry, based on their geography, economic status, health systems and access to care, age, gender, co-morbidities and a host of other characteristics. Since there has been low adoption of healthcare technology in Asia, thus far, this has limited the availability of this type of secondary data for research. That is where the ADORE registry can begin to help fill some important gaps in knowledge.
ADORE is a modern, online research platform which gives diabetes patients and their medical care providers in Asia Pacific a place to record standardized information about their diagnosis, condition, co-morbidities and treatments, including what prescriptions were given and whether they were filled, what other treatments are being used including non-prescription and complementary treatments, and if patients were hospitalized or had other costly healthcare that may not have been reported to their doctors. These data can be used to provide vital insights into the patient experience with the goal of understanding which Asian patients are affected, what treatments they are receiving, the risks and benefits of these treatments in each region and whether the benefit-risk profiles of various treatments are the same in various Asian ethnicities and health systems. The goal of assembling this information is to translate it into knowledge that can be used to identify treatments that will be effective, hopefully leading to more intelligent health care spending and driving better patient outcomes.
While still in the planning stages, ADORE promises to drive the next iteration of data collection around diabetes in Asia. The information we gather will help identify treatment patterns in Asian patients, describe effectiveness and safety for key treatment classes and product types in more diverse populations and quantify real-world treatment adherence. It will also provide information about major complications of diabetes and understanding of treatment outcomes in sociocultural subgroups.
One of the other benefits of this registry is that it will not only capture important data, but will use IQVIA state-of-the-art tools to collect and analyze the results. This is a key component of the value proposition of ADORE, as ‘big data’ on its own generates little value unless you have a sophisticated real-world design and analytical approaches to generate meaningful and actionable information.
To make the most of this vital real-world database, public and private stakeholders will need to work together to get it built and encourage its use by patients and physicians across the region, so that it can generate a robust, representative data that can be used to inform clinical practice. This registry has the potential to improve the lives of millions of people, and it will be great if IQVIA can contribute to its success.